Published in Lab Law Weekly, May 18th, 2007
Under the terms of the agreement, Novartis is granted world-wide exclusive rights for CYT002-NicQb and is responsible for late stage clinical development, manufacturing, and commercialization of the vaccine. In return, Cytos Biotechnology is eligible to receive up to CHF 600 million in upfront and potential development, regulatory approval and sales milestone payments based...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.